Stay updated on REL-1017 Adjunctive for MDD: Efficacy & Safety Clinical Trial

Sign up to get notified when there's something new on the REL-1017 Adjunctive for MDD: Efficacy & Safety Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the REL-1017 Adjunctive for MDD: Efficacy & Safety Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value (Estimated) 7 on the webpage has recently changed to 8. This change likely represents an update in the efficacy or safety assessment of REL-1017 as an adjunctive treatment for Major Depressive Disorder in the Phase 3 clinical trial.
    Difference
    0.2%
    Check dated 2024-06-06T14:46:28.000Z thumbnail image
  7. Check
    10 days ago
    Change Detected
    Summary
    The value -26 03 25 -26 03 has recently changed to 06- 05 16 (Estimated) 06- 05. This change likely represents an update or revision in the study record information related to the clinical trial for the assessment of the efficacy and safety of REL-1017 as an adjunctive treatment for Major Depressive Disorder.
    Difference
    0.8%
    Check dated 2024-06-03T13:33:59.000Z thumbnail image
  8. Check
    22 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying that adults aged 18 to 65 with Major Depressive Disorder (MDD) are eligible, along with other specific inclusion and exclusion criteria.
    Difference
    16%
    Check dated 2024-05-22T21:38:17.000Z thumbnail image
  9. Check
    44 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:32:12.000Z thumbnail image

Stay in the know with updates to REL-1017 Adjunctive for MDD: Efficacy & Safety Clinical Trial

Enter your email address, and we'll notify you when there's something new on the REL-1017 Adjunctive for MDD: Efficacy & Safety Clinical Trial page.